We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Janssen Pharmaceutical has submitted an application to the European Medicines Agency (EMA) seeking approval for subcutaneous formulation of Darzalex (daratumumab) to treat multiple myeloma.